MiR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 1849-1867

  Letelier, Pablo ^a,b   García, Patricia ^c   Leal, Pamela ^a   Álvarez, Héctor ^d   Ili, Carmen ^a   López, Jaime ^a   Castillo, Jonathan ^a   Brebi, Priscilla ^a   Roa, Juan Carlos ^c  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b UNIVERSIDAD CATÓLICA DE TEMUCO   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gallbladder cancer; MicroRNAs; miR 1; miR 145; NOZ cells

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; MICRORNA; MIRN1 MICRORNA, HUMAN; MIRN145 MICRORNA, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CELL PROLIFERATION; CELL SURVIVAL; CLUSTER ANALYSIS; DNA MICROARRAY; GALLBLADDER TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLUSTER ANALYSIS; GALLBLADDER NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902455484     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Misra S, Chaturvedi A, Misra NC and Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176.
2. Miller G and Jarnagin WR. Gallbladder carcinoma. Eur J Surg Oncol 2008; 34: 306-312.
3. Donohue JH. Present status of the diagnosis and treatment of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 2001; 8: 530-534.
4. de Aretxabala X, Losada H, Mora J, Roa I, Burgos L, Yanez E, Quijada I and Roa JC. [Neoadjuvant chemoradiotherapy in gallbladder cancer]. Rev Med Chil 2004; 132: 51-57.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
6. Du T and Zamore PD. microPrimer: the biogenesis and function of microRNA. Development 2005; 132: 4645-4652.
7. Chuang JC and Jones PA. Epigenetics and microRNAs. Pediatr Res 2007; 61: 24R-29R.
8. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005; 435: 745-746.
9. Chen CZ, Li L, Lodish HF and Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
10. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
11. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P and Stoffel M. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226-230.
12. Landthaler M, Yalcin A and Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004; 14: 2162-2167.
13. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
14. Garzon R, Fabbri M, Cimmino A, Calin GA and Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-587.
15. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6: 6.
16. Nana-Sinkam SP and Croce CM. MicroRNAs as therapeutic targets in cancer. Transl Res 2009; 157: 216-225.
17. Nana-Sinkam SP and Croce CM. Non-coding RNAs in cancer initiation and progression and as novel biomarkers. Mol Oncol 2011; 5: 483-491.
18. Nikitina EG, Urazova LN and Stegny VN. MicroRNAs and human cancer. Exp Oncol 2012; 34: 2-8.
19. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M and Garcia-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 5.
20. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Chiaro MD, Peters GJ and Giaccone G. Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. PLoS One 2010; 5: e10630.
21. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K and Fukayama M. Downregulation of MicroRNA-200 in EBV-Associated Gastric Carcinoma. Cancer Res 2010; 70: 4719-27.
22. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI and Tan M. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1). J Biol Chem 2010; 285: 21496-507.
23. Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ and Weidhaas JB. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 2011; 10: 1845-1852.
24. Mueller DW, Rehli M and Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009; 129: 1740-1751.
25. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM and de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005; 102: 19075-19080.
26. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, Li L, Huang DD, Ding J, Shen F, Zhou WP, Wu MC and Wang HY. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009; 50: 358-369.
27. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52: 297-303.
28. Kono H, Nakamura M, Ohtsuka T, Nagayoshi Y, Mori Y, Takahata S, Aishima S and Tanaka M. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep 2013; 30: 17-24.
29. Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J, Hu L, Li L, Jiang F, Chen C, Wang R, Yang Y, Jiang X, Wu M, Chen L and Wang H. MiR-20a triggers metastasis of gallbladder carcinoma. J Hepatol 2013; 59: 518-527.
30. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V and Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-378.
31. Tusher VG, Tibshirani R and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121.
32. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A and Raponi M. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009; 9: 9.
33. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K and Jacob ST. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68: 5049-5058.
34. Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H and Shi DB. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 2013; 32: 491-501.
35. Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF and Wong N. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012; 33: 1134-1141.
36. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G and Voros D. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 2013; 42: 67-71.
37. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R and Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
38. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N and Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 2009; 77: 12-21.
39. Wei W, Hu Z, Fu H, Tie Y, Zhang H, Wu Y and Zheng X. MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. Oncol Rep 2012; 28: 701-706.
40. Kusenda B, Mraz M, Mayer J and Pospisilova S. MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 205-215.
41. Farazi TA, Spitzer JI, Morozov P and Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
42. Jansson MD and Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610.
43. Akao Y, Nakagawa Y and Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006; 16: 845-850.
44. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T and Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-1920.
45. Amaral FC, Torres N, Saggioro F, Neder L, Machado HR, Silva WA Jr, Moreira AC and Castro M. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab 2009; 94: 320-323.
46. Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH and Langer F. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010; 10: 10.
47. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008; 283: 33394-33405.
48. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J and Lodish HF. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 2010; 24: 3427-37.
49. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein- Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ and Schlecht NF. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009; 174: 736-745.
50. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A, Hernandez JM, Garcia-Sanz R, Gonzalez M and San Miguel JF. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24: 629-637.
51. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM and Ambs S. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2011; 40: 3689-3703.
52. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, Shinomura Y, Imai K and Toyota M. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res 2011; 71: 5646-5658.
53. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, Tanaka Y and Dahiya R. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32: 772-778.
54. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y and Dahiya R. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010; 103: 256-264.
55. Wang SN, Chung SC, Tsai KB, Chai CY, Chang WT, Kuo KK, Chen JS and Lee KT. Aberrant p53 expression and the development of gallbladder carcinoma and adenoma. Kaohsiung J Med Sci 2006; 22: 53-59.
56. Sachdeva M and Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010; 2: 170-180.
57. Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J and Gazdar AF. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55: 2511-2515.
58. Chan JA, Krichevsky AM and Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033.
59. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and Seki N. Tumour suppressors miR-1 and miR-133a target the oncomiR-1 and miR-145 in gallbladder cancer genic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 2012; 106: 405-413.
60. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa M. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 2011; 104: 808-818.
61. Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Sasaki K, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nakagawa M, Okamoto Y and Seki N. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol 2011; 39: 1099-1107.
62. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Shozu M, Okamoto Y and Seki N. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2012; 2: 29-42.
63. Wang F, Song G, Liu M, Li X and Tang H. miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. FEBS Lett 2011; 585: 3263-3269.
64. Leone V, D'Angelo D, Rubio I, de Freitas PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco A. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab 2011; 96: E1388-1398.
65. Rani SB, Rathod SS, Karthik S, Kaur N, Muzumdar D and Shiras AS. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol 2013; 15: 1302-16.
66. Shao Y, Qu Y, Dang S, Yao B and Ji M. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int 2013; 13: 13.
67. Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, Park WS, Lee JY and Nam SW. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 2013; 335: 455-462.
68. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010; 29: 29.
69. Wang Z, Zhang X, Yang Z, Du H, Wu Z, Gong J, Yan J and Zheng Q. MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. Biochem Biophys Res Commun 2012; 427: 444-449.
70. Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN, Liu XY, Zhang YY, Li Y, Lin SG and Yu XY. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 2009; 381: 597-601.
71. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z and Yang B. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120: 3045-3052.
72. Tang Y, Zheng J, Sun Y, Wu Z, Liu Z and Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 2009; 50: 377-387.
73. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, Lin SG and Li Y. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008; 376: 548-552.
74. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N, Seki N and Nakagawa M. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2011; 48: 827-836.
75. Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM and Garzon R. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 2012; 117: 4696-4706.
76. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG and Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013; 32: 61-69.
77. Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 2013; 42: 667-675.
78. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 Suppl 1: 2-10.
79. Takahashi H and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-241.
80. Ruiz M. Participación de la vía de señalización fosfatidilinositol 3 quinasa/Akt/eNosen procesos de angiogenesis y remodelado vascular. Nefrología 2002; XXII.
81. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS and Liu ET. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991; 11: 5016-5031.
82. Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond) 2012; 122: 361-368.
83. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC and Bussolino F. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 2005; 105: 1970-1976.
84. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa M. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 2010; 30: 434-443.
85. Wu CD, Kuo YS, Wu HC and Lin CT. MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. J Biomed Sci 2012; 18: 18.
86. Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, Gotannda T, Tachiwada T, Nohata N, Yamane T, Seki N and Nakagawa M. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine- rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun 2012; 417: 588-593.
87. Noguchi S, Yamada N, Kumazaki M, Yasui Y, Iwasaki J, Naito S and Akao Y. socs7, a target gene of microRNA-145, regulates interferon-beta induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis 2013; 4: e482.
88. Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32.
89. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A and Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010; 5: e8836.
90. Chivukula RR and Mendell JT. Abate and switch: miR-145 in stem cell differentiation. Cell 2009; 137: 606-608.
91. Letelier P, Garcia P, Leal P, Ili C, Buchegger K, Riquelme I, Sandoval A, Tapia O and Roa JC. Immunohistochemical Expression of Vascular Endothelial Growth Factor A in Advanced Gallbladder Carcinoma. Appl Immunohistochem Mol Morphol 2013; [Epub ahead of print].